Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2026 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as...
December 17, 2025 07:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic...
December 12, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
December 08, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
November 20, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Participate in 8th Annual Evercore Healthcare Conference

EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
November 17, 2025 06:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Appoints Kristian Humer as Chief Financial Officer

EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
November 14, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
November 10, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive...
November 06, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Jefferies 2025 London Healthcare Conference

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
November 06, 2025 06:23 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...